Scarica l'app Stockscreener
46.91
0.59%
-0.28
Dopo l'orario di chiusura:
47.72
0.81
+1.73%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché TNXP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$47.19
Aprire:
$48.74
Volume 24 ore:
1.48M
Relative Volume:
1.60
Capitalizzazione di mercato:
$345.13M
Reddito:
-
Utile/perdita netta:
$-121.02M
Rapporto P/E:
-4.1661
EPS:
-11.26
Flusso di cassa netto:
$-114.09M
1 W Prestazione:
+14.78%
1M Prestazione:
+36.68%
6M Prestazione:
+99.19%
1 anno Prestazione:
-17.82%
Intervallo 1D:
$45.50
$48.80
Intervallo di 1 settimana:
$40.80
$50.40
Portata 52W:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Nome
Tonix Pharmaceuticals Holding Corp
Settore
Industria
Telefono
212-980-9155
Indirizzo
26 MAIN STREET, SUITE 101, CHATHAM, NY
Confronta TNXP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
46.91 | 300.69M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-04-18 | Iniziato | Noble Capital Markets | Outperform |
| 2019-04-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Reiterato | Oppenheimer | Outperform |
| 2015-11-04 | Iniziato | Cantor Fitzgerald | Buy |
| 2015-06-12 | Iniziato | Oppenheimer | Outperform |
| 2015-02-17 | Reiterato | ROTH Capital | Buy |
| 2014-09-29 | Reiterato | ROTH Capital | Buy |
Mostra tutto
Tonix Pharmaceuticals Holding Corp Borsa (TNXP) Ultime notizie
Tonix Pharmaceuticals Holding Corp. Stock Analysis and ForecastHigh-octane financial growth - jammulinksnews.com
Is Tonix Pharmaceuticals Holding Corp. a good long term investmentUnmatched profit potential - Autocar Professional
What drives Tonix Pharmaceuticals Holding Corp. stock priceFree Stock Market Mentorship - Autocar Professional
What analysts say about Tonix Pharmaceuticals Holding Corp. stockSuperior returns - Autocar Professional
Tonix targets August PDUFA date for Fibromyalgia drug candidate, advances mpox vaccine strategy - Proactive financial news
Are TNXP Shares Ready for a Comeback? - StocksToTrade
Tonix Pharma Plans Sales Force for TNX-102 SL - TipRanks
Tonix Pharmaceuticals ($TNXP) Skyrockets 284% in 2025: Earnings Catalysts.... - Investing.com India
Tonix reports TNX-801 vaccine shows promise against mpox By Investing.com - Investing.com South Africa
Tonix Pharmaceuticals Shares Climb on Encouraging TNX-801 Vaccine Results - MSN
Tonix Pharmaceuticals Announces Presentation of New Data on - GlobeNewswire
Tonix Pharma stock up after data for pain drug (TNXP:NASDAQ) - Seeking Alpha
Tonix Pharmaceuticals stock rises on promising TNX-801 vaccine data By Investing.com - Investing.com India
Tonix Pharmaceuticals stock rises on promising TNX-801 vaccine data - Investing.com Australia
Tonix reports TNX-801 vaccine shows promise against mpox - Investing.com
Tonix Pharma Unveils Promising TNX-801 Vaccine Findings - TipRanks
Revolutionary Mpox and Smallpox Vaccine Achieves 100,000-Fold Safety Improvement with Single-Dose Protection - Stock Titan
Tonix Pharmaceuticals shares rise 1.75% premarket after publishing positive Phase 3 trial results for TNX-102 SL. - AInvest
Tonix Pharmaceuticals Announces On-line Publication of - GlobeNewswire
Tonix Pharmaceuticals' TNX-102 SL: A Breakthrough in Fibromyalgia Treatment and Its Implications for Investors - AInvest
Tonix’s fibromyalgia drug shows positive results in phase 3 trial By Investing.com - Investing.com South Africa
Tonix’s fibromyalgia drug shows positive results in phase 3 trial - Investing.com Australia
Tonix Pharma Publishes Phase 3 Trial Results - TipRanks
Tonix Pharmaceuticals Announces Publication of Positive Phase 3 RESILIENT Trial Data for TNX-102 SL in Fibromyalgia Management - Nasdaq
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine - Yahoo Finance
Breakthrough Fibromyalgia Treatment Shows Superior Pain Relief in Phase 3 Trial, FDA Decision Looms - Stock Titan
Tonix Pharmaceuticals Announces Efficacy and Safety of Single-Dose TNX-801 Vaccine Against Monkeypox - Quiver Quantitative
Tonix Pharmaceuticals Announces Oral Presentation on Mpox - GlobeNewswire
Breakthrough: New Single-Dose Vaccine Demonstrates 100% Protection Against Deadly Mpox Challenge - Stock Titan
Tonix Pharmaceuticals Announces Peer-Reviewed Publication - GlobeNewswire
Major Cancer Treatment Breakthrough: New Drug Combo Defeats Immunotherapy Resistance in Gastric Cancer - Stock Titan
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to Russell 3000E Index - MarketScreener
Tonix Pharmaceuticals Joins Elite Russell Indexes Ahead of Major FDA Decision - Stock Titan
Tonix Pharmaceuticals Holding Corp.(NasdaqCM: TNXP) added to Russell 2500 Index - MarketScreener
How To Trade (TNXP) - news.stocktradersdaily.com
Tonix Pharmaceuticals Reports Promising Phase 3 Results for Fibromyalgia Treatment at EULAR 2025 - citybuzz -
Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL - GuruFocus
Tonix Pharmaceuticals: Big Risk, Bigger RewardInitiating With A Buy (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharma Presents Data at Rheumatology Congress - TipRanks
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment a - GuruFocus
Tonix Pharmaceuticals (TNXP) Highlights Fibromyalgia Treatment at EULAR 2025 | TNXP Stock News - GuruFocus
Tonix Pharmaceuticals Presented Data and Analyses of - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Shows Breakthrough Results, FDA Decision Approaches - Stock Titan
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP St - GuruFocus
Tonix Pharmaceuticals Announces Appointment of Commercial - GlobeNewswire
Tonix Pharmaceuticals Strengthens Board with Appointment of Jim Hunter - citybuzz -
Tonix Pharmaceuticals Announces Appointment of Commercial Indust - GuruFocus
Tonix Pharmaceuticals Appoints James “Jim” Hunter To Board - citybiz
Tonix Pharmaceuticals (TNXP) Welcomes New Board Member | TNXP Stock News - GuruFocus
Tonix Pharma Appoints James Hunter to Board - TipRanks
Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion? (NASDAQ:TNXP) - Seeking Alpha
Tonix Pharmaceuticals Holding Corp Azioni (TNXP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):